The Institute for Clinical and Economic Review on Wednesday, May 22, released a draft evidence report for two gene therapies and a corticosteroid for the treatment of Duchenne muscular dystrophy (DMD).
According to a press release, the report looks at Sarepta’s gene therapies, eteplirsen and golodirsen, as well as PTC Therapeutics’s corticosteroid deflazacort.
The report will be open to public comment until 5 p.m. EST June 18. The evidence report, which will be published July 11, will be discussed during the July 25 meeting of the New England Comparative Effectiveness Public Advisory Council.
To read the draft evidence report, click here.
